Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure

7Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Melanoma cell adhesion molecule (MCAM) is a marker of endothelial damage. MCAM diagnostic and prognostic value was assessed in chronic heart failure (CHF). Materials & methods: 130 CHF patients and 32 controls were included in the study. Telephone follow-up lasted one year. End points were: death from all causes, and hospitalization with CHF exacerbation. Results: MCAM was higher in patients than in controls (p = 0.01). Receiver operator curve analysis revealed that MCAM may serve as a predictor of death (area under the curve: 0.8404; p < 0.002). Patients with MCAM above 500 ng/ml had worse prognosis (p = 0.03). NT-proBNP and age were independent predictors of death in multivariate analysis. Conclusion: The increased MCAM indicates endothelial damage in CHF and may serve as a marker of worse prognosis in these patients.

Cite

CITATION STYLE

APA

Banach, J., Grochowska, M., Gackowska, L., Buszko, K., Bujak, R., Gilewski, W., … Sinkiewicz, W. (2016). Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure. Biomarkers in Medicine, 10(7), 733–742. https://doi.org/10.2217/bmm-2016-0053

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free